Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Random, 95% CI
Armstrong 2004	0	0	0	0		Not estimable
Bardhan 2007	243	293	248	288	8.0%	0.96 [0.90, 1.03]
Castell 2002	0	0	0	0		Not estimable
Eggleston 2009	0	0	0	0		Not estimable
Fennerty 2005	410	498	388	501	8.9%	1.06 [1.00, 1.13]
Gilesen 2004	70	76	69	77	5.2%	1.03 [0.93, 1.14]
Glatzel 2007	0	0	0	0		Not estimable
Howden 2002	123	138	127	139	7.2%	0.98 [0.90, 1.05]
Kahrilas 2000	615	654	565	650	12.7%	1.08 [1.04, 1.12]
Labenz 2005	1431	1562	1413	1589	14.4%	1.03 [1.01, 1.05]
Moraes-Filho 2014	253	279	246	284	9.3%	1.05 [0.99, 1.11]
Richter 2001	1139	1216	1018	1209	13.7%	1.11 [1.08, 1.14]
Schmitt 2006	531	576	514	572	12.6%	1.03 [0.99, 1.06]
Scholten 2003	0	0	0	0		Not estimable
Zheng 2009	62	65	178	199	7.8%	1.07 [0.99, 1.15]
Total (95% CI)		5357		5508	100.0%	1.04 [1.02, 1.07]
Total events	4877		4766			

Heterogeneity: Tau² = 0.00; Chi² = 32.49, df = 9 (P = 0.0002); I² = 72%
Test for overall effect: Z = 3.04 (P = 0.002)

Supplementary Figure 11. Forest plot of symptom relief in subjects on esomeprazole 40 mg per day and other standard dose proton pump inhibitors at 8 weeks. M-H, Mantel-Haenszel.